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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common 
malignancies across the globe, especially in Asia and south-
ern Africa.1 Through a diagnosis followed by systemic exami-
nation, HCC can be classified into early, mid, and late (ad-
vanced) stages. Surgical resection, liver transplantation,2 or 
local ablation have generally been used to treat early- and mid-
stage HCC, and the 5-year survival rate could be as high as 60–
70%.2 However, owing to the lack of effective treatment options 
and underlying liver disease, patients diagnosed at an advanced 
stage or with progression experience a much more dismal prog-
nosis after locoregional therapy.3 Until sorafenib was used as 
a first-line therapy, there was no systemic therapy to improve 
survival in patients with late-stage HCC.4,5
Sorafenib, which has anti-proliferative and anti-angiogenic 
effects, is an oral multikinase inhibitor.6 It can inhibit several 
cellular signaling pathways, including those of Raf/mitogen-
activated protein kinase (MAPK), extracellular signaling-regu-
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lated kinase (ERK), as well as the receptors of vascular endothe-
lial growth factor and platelet-derived growth factor.6,7 As the 
standard care for patients with advanced HCC, sorafenib has 
been proven to have the capacity to inhibit HCC cell prolifera-
tion, angiogenesis, and so on.8,9 However, the promising treat-
ment of HCC with sorafenib has limited benefits to survival 
and very low rates of tumor response, where some patients 
with HCC even exhibit no initial response to sorafenib,3,10 in-
dicating the existence of both primary and acquired resis-
tances of HCC cells to sorafenib.9 The primary resistance of 
HCC to sorafenib has been shown to be due to genetic hetero-
geneity.10 While sorafenib inhibits several cellular signaling 
pathways as a multikinase inhibitor, it simultaneously or se-
quentially activates the addiction switches and compensatory 
pathways.9 Although several mechanisms have been proposed, 
as for the acquired resistance of HCC cells to sorafenib, the exact 
mechanisms remain unclear.11,12
The multifunctional cytokine transforming growth factor-β 
(TGF-β) orchestrates an intricate signaling network to modu-
late tumorigenesis and progression by exerting a dynamic ef-
fect on cancer cells.13 Early in the carcinogenesis process, TGF-β1 
suppresses tumors and arrests cell growth, whereas in later 
and more advanced tumor stages, TGF-β1 potentiates epithe-
lial-to-mesenchymal transition, angiogenesis, tumor progres-
sion, invasion, and metastasis.14,15 Previous studies have shown 
that TGF-β1 was overexpressed in HCC cells, and clinical stud-
ies showed higher blood levels of TGF-β1 in patients with HCC 
than in patients with chronic hepatitis or cirrhosis.16 Further-
more, HCC cells with a higher IC50 in response to sorafenib 
tended to have higher TGF-β1 mRNA expression,16 and TGF-β2 
was overexpressed in some HCC cell lines and patient cohorts 
and a correlation was found between high TGF-β2 expression 
and lower survival rates (p<0.01).17 Thus, the TGF-β signaling 
pathway should be explored as a therapeutic target for pa-
tients with advanced HCC.
MAPKs are essential components of intracellular signal tr-
ansduction, in which p38 MAPK plays an essential role in the 
regulation of gene expression and in controlling cellular resp-
onses to the environment, cell growth, and apoptosis. These 
features have previously made p38 MAPK a molecular target 
for drug development in the treatment of many human diseas-
es, most notably in the treatment of a variety tumors.18  The in-
volvement of the p38 MAPK cascade in the apoptotic pathway 
has been demonstrated in two hepatoma cell lines, HepG2 and 
Huh7, wherein the activation of p38 MAPK inhibited cell gr-
owth and induced apoptosis.19 The apoptosis of human hepa-
toma cell lines results from increased caspase 3 activity via the 
activation of p38 MAPK: Bid cleavage and cytochrome c re-
lease are modulated by p38 MAPK activation.19 In human HCC 
patients, the activities of p38 MAPK and MKK6 were signifi-
cantly lower than in adjacent uninvolved liver tissue, whereas 
the activity of ERK1/2 was significantly increased in malignant 
lesions.19,20 Treatment with sorafenib has been shown to in-
hibit p38α kinase activity in vitro by targeting the DFG-out 
conformational state of p38α.21 The reduction of p38 activity 
as a result of sorafenib treatment could be one of the causes of 
resistance, therefore, it should be a potential target to induce 
more effective cell death in HCC patients.
Adenovirus serotype 5 is the most commonly used viral vec-
tor in cancer gene therapies human serotype due to their high 
efficiency, broad range of host transduction, easy genome ma-
nipulation, and non-integration into the host genome.22 In this 
research, therefore, we designed adenovirus-delivered TGF-β 
short hairpin RNAs (shRNAs) to knock down TGF-β expres-
sion. The reduction in TGF-β expression resulted in an increase 
of p38 activity, thus activating the cellular death signal. When 
TGF-β shRNA was combined with sorafenib, HCC cells be-
came highly sensitized to sorafenib, and the efficiency of so-
rafenib against advanced HCC was significantly increased.
MATERIALS AND METHODS
Cell culture 
Hep-3B, Huh7, and SK-Hep-1 cells were cultured in Dulbecco’s 
modified Eagle’s medium with 10% fetal bovine serum (FBS). 
SNU-182, SNU-398, and SNU-449 cells were cultured in RPMI 
with 10% FBS. Cells were maintained in a 37°C humidified at-
mosphere containing 5% CO2.
Reagents
Antibodies to GAPDH and sorafenib were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies 
to p38, phospho-p38, phospho-Akt (Ser473), phospho-ERK 
(Thr202/Tyr204), phospho-p65 (Ser536), phospho-Src 
(Tyr416), MKK3, and MKK6 were purchased from Cell Signal-
ing Technology (Beverly, MA, USA). All other chemicals were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Construction of adenoviral vectors
For the expression of siRNAs targeting human TGF-β1 or TGF-β2, 
each annealed sequences for shRNA were cloned into a 
pSP72ΔE3-U6/H1 vector after BamHI/HindIII digestion. These 
vectors, designated pSP72ΔE3-U6-shTGF-β1 and pSP72ΔE3-
U6-shTGF-β2 (E3 shuttle vector), were linearized by XmnI di-
gestion, and co-transformed into E. coli BJ5183 together with 
the SpeI-digested adenoviral vector (dl324-IX) for homolo-
gous recombination. The detailed informations about the 
construction of TGF-β shRNAs was previously described.23 The 
recombinant adenoviral vectors with abbreviated names are 
as follows: 
NC: Ad-IX-ΔE1--ΔE3, control virus.
shT1: Ad-IX-ΔE1-ΔE3-U6-shTGFβ1, virus expressing shR-
NA of human TGFβ1 (shTGFβ1).
shT2: Ad-IX-ΔE1-ΔE3-U6-shTGFβ2, virus expressing shR-
NA of human TGFβ2 (shTGFβ2).
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MTS viability assays
The CellTiter 96® Aqueous Assay kit (Promega, Madison, WI, 
USA) comprises solutions of a novel tetrazolium compound 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an 
electron coupling reagent (phenazine ethosulfate). MTS is 
bioreduced by cells into a formazan product that is soluble in 
tissue culture media. The conversion of MTS into aqueous, 
soluble formazan is carried out by dehydrogenase enzymes 
found in metabolically active cells. Subsequently, HCC cell 
lines were treated with varying doses of sorafenib (0, 2.5, 5, 10, 
15, 20, and 25 μM) in 96-well plates for 24 h. The absorbance 
of formazan at 490 nm was measured directly from 96-well 
plates without additional processing, and the quantity of forma-
zan product measured at 490 nm is directly proportional to the 
number of living cells in culture.
Western blot analyses
Cells were lysed with 1X Laemmli sample buffer (62.5 mM 
Tris, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 0.002% 
bromophenol blue) and protein concentration was determined 
using the BCA Protein Assay Kit (Thermo Scientific, Fremont, 
CA, USA). Then, protein samples were resolved by sodium do-
decyl sulfate-polyacrylamide gel electrophoresis, and gels 
were electro-transferred onto polyvinylidene difluoride mem-
branes (Millipore, Billerica, MA, USA). Immunodetection was 
performed using anti-phosho-Akt (p-Akt), anti-phosho-Src 
(p-Src), anti-phosho-p65 (p-p65), anti-phoshoERK (p-ERK), 
anti-phosho-p38 (p-p38), anti-p38, anti-MKK3, anti-MKK6 and 
anti-GAPDH primary antibodies, with the chemiluminescent 
and fluorescent image analysis system (Syngene, Cambridge, UK).
Real-time quantitative polymerase chain reactions
Cells were lysed with Trizol reagent (Life Technologies, Carls-
bad, CA, USA) and the total RNA was isolated via chloroform 
extraction. RNA concentration was determined with a Nano-
drop 2000 (Thermo Scientific). The real-time polymerase chain 
reaction (PCR) was performed using a Power SYBR Green 
RNA-to-CT 1-Step Kit (Life Technologies). The reaction mixture 
contained the reverse transcriptase enzyme mix, reverse tran-
scription PCR mix, forward primer, reverse primer, RNA tem-
plate, and nuclease-free water. Human TGF-β1 cDNA was am-
plified using the forward primer 5’-CAAGGGCTACCATGCC 
AACT-3’ and the reverse primer 5’-AGGGCCAGGACCTTG 
CTG-3’. Human TGF-β2 cDNA was amplified using the for-
ward primer 5’-GCTGCCTACGTCCACTTTACAT-3’ and the 
reverse primer 5’-ATATAAGCTCAGGACCCTGCTG-3’. Human 
β-actin was amplified using the forward primer 5’-ACTCTTC 
CAGCCTTCCTT-3’ and the reverse primer 5’-ATCTCCTTCT 
GCATCCTGTC-3’.
Enzyme-linked immunosorbent assays
Cells were plated in the wells of six-well plates at a density of 
1×105 cells/well. Supernatants were collected after 48 hr. The 
levels of TGF-β1 and TGF-β2 expression were determined by 
an enzyme-linked immunosorbent assays (ELISA) according 
to the manufacturer’s instructions (R&D Systems, Minneapo-
lis, MN, USA).
 
Clonogenic assays
Cells were plated into six-well plates at a density of 1×105 cells/
well. Subsequently, HCC cell lines were treated with of vari-
ous concentrations (0, 2.5, 5, 10, 15, or 20 μM) sorafenib (24 hr) 
or treated with 2.5 μM sorafenib (12 hr) followed by a pre-treat-
ment with adenoviral vectors (NC, shT1, shT2) for 24 hr. Cells 
were trypsinized and plated into six-well plates at densities of 
5×103 or 1×104 cells/well. They were then monitored daily by 
microscopy. When cells exhibited colonies, surviving cells 
were fixed with 4% paraformaldehyde and stained with 0.5% 
crystal violet.
 
Animal studies
Tumors were implanted subcutaneously in the abdomen of 
BALB/c nude mice via the injection of SNU-449 human liver 
cancer cells (1×107) in 100 μL of Hank’s balanced salt solution 
(Gibco BRL, Carlsbad, CA, USA). When tumors reached a size 
range of 70–100 mm3, animals were randomized into 5 groups 
of 8 animals each per group [phosphate buffered saline (PBS), 
sorafenib, NC+sorafenib, shT1+sorafenib, shT2+sorafenib]. 
Animals in adenoviral groups or the control group (PBS) were 
administered adenoviruses intratumorally [virus; 1×109 PFU 
(plaque-forming units) per tumor in 50 μL of PBS] on days 1, 3, 
and 5. Sorafenib (30 mg/kg) was administered once daily by 
gavage for 10 days. The regression of tumor growth was as-
sessed by measuring the length (L) and width (W) of each tumor. 
Tumor volume was calculated using the following formula: 
volume=0.52×L×W2.
Statistical analyses
The data are expressed as mean±standard error. Statistical 
comparisons (students t-test) were made using Graph Pad (Sy-
stat Software, Inc., Chicago, IL, USA). p-values less than 0.05 were 
considered statistically significant (*p<0.05, †p<0.01, ‡p<0.001).
   
   
RESULTS
Sorafenib treatment induced changes in several 
signaling pathways in HCC cell lines 
To evaluate the impact of sorafenib in vitro, we first identified 
the IC50 of sorafenib in different HCC cell lines. The MTS as-
say showed that the IC50 of sorafenib in HCC cell lines ranged 
from 7.5 μM to 15 μM (Fig. 1A). Subsequently, we examined 
various key signaling pathway molecules, including p-p38, 
p-p65, p-Src, and p-ERK by using western blot analyses, in 
HCC cell lines after treatment with sorafenib IC50 concentra-
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Fig. 1. Effect of sorafenib on different HCC cell lines. (A) Hep-3B, Huh7, SK-Hep-1, SNU-182, SNU-398, and SNU-449 cells were treated with sorafenib 
in a dose-dependent manner. After 24 h, cell viability was tested via a MTS viability assay. IC50 of each cell line is indicated in each rectangle. Error 
bars represent the standard error from three independent experiments. (B) HCC cell lines were treated with sorafenib at IC50 concentrations, respec-
tively. After 24 h, the expressions of p-p38, p38, p-ERK, p-Akt, p-Src, p-p65, and GAPDH were detected by western blot analysis. (C) HCC cell lines 
were treated with sorafenib in a dose-dependent manner for 24 h. and incubated for additional 14 days for clonogenic assays. (D) HCC cell lines were 
treated with a low dose of sorafenib (2.5 μM) for 24 h, and changes in the levels of p-Akt p-p65, p-ERK, and p-p38 expression were then detected by 
western blot analysis. HCC, hepatocellular carcinoma.
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tions, and observed that phospho-ERK activity was reduced 
by sorafenib treatment. The activity of p-p38 was also decreased 
in many HCC cells, which may inhibit the death-related signal-
ing pathway (Fig. 1B). We then performed a clonogenic assay 
to confirm the cell viability of HCC cells after dose-dependent 
treatments with sorafenib, and observed that many HCC cells 
survived treatment, even in the presence of high doses of sora-
fenib, indicating low sensitivity of HCC cells to sorafenib and 
their resistance to this form of treatment (Fig. 1C). As shown in 
Fig. 1D, p-Akt and p-p65 were increased by incubating cell lines 
with 2.5 μM sorafenib for 24 h, whereas p-p38 levels were also 
more clearly reduced during the treatment. The increased activi-
ties of p-p65 and p-Akt (Fig. 1D) signify that cell lines were in 
fact resistant to sorafenib. Likewise, the inhibition of p-p38 was 
observed under conditions of sorafenib resistance, suggesting 
that it may play a role in inducing resistance to sorafenib in 
HCC cell lines.
p38-mediated cell death pathway was inhibited by 
treatment with sorafenib
To increase the activity of p38, we employed the constitutive 
form of MKK3/6 (MKK3/6E provided by Addgene; Cambridge, 
MA, USA), which has the ability to induce p38 phosphoryla-
tion without any stimulation. Fig. 2A and D show that HCC cell 
lines transfected with the MKK3/6E plasmid clearly increased 
p38 phosphorylation (Fig. 2A and D), and the cell viability assay 
showed that the activation of p38 induced massive cell death 
in HCC cell lines (Fig. 2B). In addition, when treated with both 
the MKK3/6E plasmid and sorafenib, cell viability in HCC cell 
lines was significantly reduced in comparison to cell lines treat-
ed with sorafenib only (Fig. 2B). Clonogenic assays also con-
firmed that cell colonies were reduced by MKK3/6E transfec-
tion in comparison to control plasmid, and that fewer cell co-
lonies formed in groups co-treated with MKK3/6E and sora-
fenib than in cells treated with sorafenib alone (Fig. 2C). In ad-
dition, p-Akt and p-p65 were reduced in response to co-treat-
ment with MKK3/6E and sorafenib (Fig. 2D), suggesting that 
p38 activity, which was inhibited by sorafenib, effectively re-
duced the cytotoxicity of sorafenib and increased the survival 
potential of HCC cell lines (Fig. 2C and D). Thus, we can sur-
mise that the inhibition of p38 activity as a result of sorafenib 
treatment was the underlying mechanism of sorafenib resis-
tance in HCC cell lines, and that an increase in the activity of 
p-p38 as a result of sorafenib treatment overrode sorafenib re-
sistance in HCC cell lines.  
TGF-β expression was reduced by sorafenib treatment 
in HCC cell lines
In order to clarify the changes in TGF-β expression as a result of 
sorafenib treatment, we analyzed changes in the mRNA levels 
of TGF-β by real-time PCR. Fig. 3A show that, while treatment 
with low concentrations (2.5 μM) of sorafenib did not signifi-
cantly alter TGF-β expression (p>0.05), the expression was sig-
nificantly (p<0.05) reduced at high concentrations (20 μM). In 
addition, TGF-β expression was increased under conditions 
of sorafenib resistance (Fig. 3B), suggesting that decrease of 
TGF-β expression could reduce the resistance of HCC cell lines 
to sorafenib and more effectively induce cell death. Interest-
ingly, when TGF-β expression was knocked down by shRNA, 
phosphorylation of p38 was also increased (Fig. 3C). 
Sorafenib combined with adenovirus expressing 
shRNA against TGF-β was more effective for 
inducing cell death in HCC cell lines
Next, we investigated whether the cell death could be increased 
by low concentrations (2.5 μM) of sorafenib when combined 
with shRNA against TGF-β. As shown in Fig. 3D and E, phos-
phorylation of p38 was increased in response to this combined 
treatment compared to sorafenib-pretreated NC virus-infected 
control group, and cell viability was lower than in the sorafenib-
pretreated NC virus-infected control group. These results sug-
gest that TGF-β down-regulation is capable of increasing the 
cytotoxicity of sorafenib by overcoming sorafenib-induced 
p38 inactivation. 
Anti-tumor effect of sorafenib combined with an 
adenovirus expressing shTGF-β in xenograft 
animal models
As described above, a series of in vitro experiments confirmed 
that an adenovirus expressing shTGF-β increased the activity 
of p38, thereby decreasing the resistance of HCC cell lines to 
sorafenib. Subsequently, in order to further confirm the anti-
tumor effect of this combination therapy, and whether this th-
erapy is able to override the resistance of HCC tumor cells to 
sorafenib, we designed an in vivo experiment in xenograft an-
imal models. 
Fig. 4A shows that treatment with adenovirus expressing 
shTGF-β1 or shTGF-β2 in combination with sorafenib dis-
played increased anti-tumor abilities in comparison to sora-
fenib alone. This suggests that while these treatments did ef-
fectively reduce the resistance of HCC tumor cells to sorafenib, 
these treatments did not result in a complete reduction in re-
sistance. Despite these outcomes, we observed no differences 
in tumor regression in response to shTGF-β1 and shTGF-β2 
(Fig. 4A). The survival rate of the animals in our study indicated 
that the combination therapy of adenovirus expressing shTGF-β1 
or 2 with sorafenib was the most effective (Fig. 4B).
DISCUSSION
In the present study, we have demonstrated that a low concen-
tration of sorafenib (2.5 μM) can inhibit the activity of p-p38, 
however, no significant cell death appeared in the low-dose 
sorafenib treatment. After the low-dose treatment, the activi-
ties of p-Akt and p-p65 were increased. Thus, we can infer that 
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Fig. 2. MKK3/6E induced p-p38 activation and massive cell death in HCC cell lines. (A) Hep-3B, Huh7, SNU-398, and SNU-449 cells were transfected 
with the pCDNA3-MKK3/6E plasmid (1 μg) for 24 h, and treated with sorafenib (2.5 μM) for 24 h. Protein expressions of MKK3, MKK6, p-p38, and GAP-
DH were estimated via western blot analysis. (B) Hep-3B, Huh7, SNU-398, and SNU-449 cells were transfected with the pCDNA3-MKK3/6E plasmid (1 
μg) for 24 h and treated with sorafenib in a dose-dependent manner for 24 h. Cell viability was examined using a MTS viability assay. Error bars repre-
sent the standard error from three independent experiments. ‡p<0.001. HCC, hepatocellular carcinoma.
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a decrease of p-p38 is the underlying mechanism responsible 
for sorafenib resistance in HCC cell lines. In other words, 
sorafenib-induced multikinase inhibition23 can be retarded or 
even inhibited by p38 inhibition due to the steric hinderance of 
sorafenib to p38,24 which makes a potential of increase of sur-
vival signals such as p65 or src depending on the cellular con-
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and SNU-449 cells were transfected with the pCDNA3-MKK3/6E plas-
mid (1 μg) for 24 h, and treated with sorafenib (2.5 μM) for 24 h. Protein 
expressions of MKK3, MKK6, p-p38, p-Akt, p-p65 and GAPDH were esti-
mated via western blot analysis. HCC, hepatocellular carcinoma.
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D
text. Therefore, after inhibition of p38 activation by sorafenib 
and resultant acquisition of resistance, survival signals such 
as p65 or src can be increased indirectly depending on the can-
cer cell types.
We used MKK3/6E to verify that when the activity of p-p38 
is increased, cell death is induced and sorafenib resistance is 
overcome. As MKK3/6 is upstream of the p38 signal in the sig-
nally pathway, its activity can induce the phosphorylation of 
p38. It has been shown that the structure of MKK3/6E is such 
that MKK3/6E is able to activate p38 without an external stim-
ulus.25 Our results show that MKK3/6E can significantly im-
prove the activity of p-p38 and induce cell death in a signifi-
cantly large number of cells (p<0.05). When treatment with 
MKK3/6E was combined with sorafenib, p-p38 activity was 
significantly increased in comparison to the activity observed 
in cells treated with sorafenib alone, but was lower in compari-
son to the p-p38 activity of cells treated with MKK3/6E alone. 
MTS and clonogenic assays confirmed that the combined ap-
plication was better than treatment with sorafenib alone. It can 
be seen that in response to the low-dose sorafenib treatment, 
p-p38 activity was reduced, suggesting the mechanism in-
volved in the resistance of HCC cells to sorafenib.
In this study, we observed that cell viability and the expres-
sion of TGF-β were increased, when HCC cells exhibited drug 
resistance after treatment with a low concentration of sorafenib. 
We have also demonstrated increased activities of p-Akt and 
p-p65 under conditions of sorafenib resistance, when TGF-β 
expression was clearly and positively correlated with sorafenib 
drug resistance. On the other hand, however, TGF-β expres-
sion was significantly decreased and cell viability was notice-
ably inhibited in response to treatment with a high concentra-
tion  of sorafenib (20 μM). These results indicate that the 
reduction in cell viability in response to high concentration of 
sorafenib (20 μM) was associated with decreased TGF-β ex-
pression. As a result of this, therefore, we targeted TGF-β, knock-
ing down TGF-β expression by using shRNA in order to im-
prove the rate of cell death and reduce drug resistance. 
In this study, the reduced expression of TGF-β by shRNA not 
only increased the activity of p-p38, but also reduced both cell 
viability and drug resistance. Although the clonogenic assay 
showed that the combined application significantly improved 
cytotoxicity, the treatment, however, did not completely elimi-
nate the formation of cell colonies from every cancer cells ex-
amined (Fig. 3E). In order to further clarify the anti-tumor ef-
fect, as well as the ability of this combination treatment to 
overcome drug resistance, therefore, an animal model was es-
tablished using subcutaneous abdominal injections of an 
HCC cell line (SNU-449) into BALB/c nude mice. The result sh-
owed incomplete regression of tumor in mice, suggesting that 
we should consider adding a new target in order to further im-
prove cytotoxicity, and to more effectively overcome sorafenib 
resistance. In the future, the use of oncolytic adenoviruses ex-
pressing combined therapeutic genes should be explored, and 
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Fig. 3. Changes in TGF-β expression in response to sorafenib treatment in HCC cell lines. (A) Hep-3B, Huh7, SK-Hep-1, SNU-182, SNU-398, and SNU-
449 cells were treated with sorafenib (2.5 μM, IC50) for 24 h, and TGF-β mRNA was estimated by RT-PCR. Error bars represent the standard error from 
three independent experiments. (B) Hep-3B, Huh7, SK-Hep-1, SNU-398, and SNU-449 cells were treated with sorafenib (2.5 μM) for 24 h and then in-
cubated for additional 14 days for sufficient acquisition of resistance. TGF-β1/2 expression was then detected via ELISA. Error bars represent the 
standard error from three independent experiments. *p<0.05, †p<0.01, ‡p<0.001. TGF-β, transforming growth factor-β; HCC, hepatocellular carcinoma; 
RT-PCR, real-time polymerase chain reaction; ELISA, enzyme-linked immunosorbent assays; SR, sorafenib resistance.
0.8
0.6
0.4
0.2
0.0
0.20
0.15
0.10
0.05
0.00
0.06
0.04
0.02
0.00
0.5
0.4
0.3
0.2
0.1
0.0
0.4
0.3
0.2
0.1
0.0
0.10
0.08
0.06
0.04
0.02
0.00
0.15
0.10
0.05
0.00
0.20
0.15
0.10
0.05
0.00
TG
F-
β1
 co
nc
en
tra
tio
n 
(n
g/
m
L)
TG
F-
β2
 co
nc
en
tra
tio
n 
(n
g/
m
L)
TG
F-
β1
 co
nc
en
tra
tio
n 
(n
g/
m
L)
TG
F-
β2
 co
nc
en
tra
tio
n 
(n
g/
m
L)
TG
F-
β1
 co
nc
en
tra
tio
n 
(n
g/
m
L)
TG
F-
β2
 co
nc
en
tra
tio
n 
(n
g/
m
L)
TG
F-
β1
 co
nc
en
tra
tio
n 
(n
g/
m
L)
TG
F-
β2
 co
nc
en
tra
tio
n 
(n
g/
m
L)
Hep-3B Huh7SK-Hep-1 SK-Hep-1
* *† ‡
SNU-398 SNU-398SNU-449 SNU-449
‡ ‡* *
Cell only Cell onlyCell only Cell only
Cell only Cell onlyCell only Cell only
SR SRSR SR
SR SRSR SR
A
B
‡
‡
†
‡ ‡
‡
‡
907
Dongxu Kang, et al.
https://doi.org/10.3349/ymj.2017.58.5.899
Fig. 3. Changes in TGF-β expression in response to sorafenib treatment in HCC cell lines. (C) SK-Hep-1, SNU-182, SNU-398, and SNU-449 cells were 
infected by defective adenoviruses (NC, shT1, and shT2) at 50 MOI. After 2 days, protein expression of p-p38 was detected via western blot analysis. 
(D) Huh7, SK-Hep-1, SNU-182, SNU-398, and SNU-449 cells were infected by defective adenoviruses (NC, shT1, and shT2) at 50 MOI. After 36 h, cells 
were treated with low concentration (2.5 μM) of sorafenib for 12 h. Changes in the protein expression of p38 and p-p38 were detected by western blot 
analysis. (E) SK-Hep-1, SNU-182, SNU-398, and SNU-449 cells were infected by defective adenoviruses (NC, shT1, and shT2) at 50 MOI. After 36 h, 
cells were treated with low concentration of sorafenib (2.5 μM) for 12 h, and were incubated for additional 14 days for clonogenic assays. TGF-β, 
transforming growth factor-β; HCC, hepatocellular carcinoma; NC, negative control; MOI, multiplicity of infection.
p-p38
GAPDH
SK-Hep-1 SNU-182
    NC       shT1    shT2      NC       shT1      shT2 
SNU-398 SNU-449
NC       shT1     shT2     NC      shT1     shT2 
Cell only
NC+
sorafenibSorafenib
shT1+
sorafenib
shT2+
sorafenib
Huh7
SNU-182
SK-Hep-1
SNU-398
SNU-449
p38
p-p38
GAPDH
p38
p-p38
GAPDH
p38
p-p38
GAPDH
p38
p-p38
GAPDH
p38
p-p38
GAPDH
SNU-182
SNU-449
Huh7
Cell
only  NC 
Sorafenib
2.5 μM shT1 shT2 
Sorafenib 2.5 μM
SNU-398
SK-Hep-1
C
D
E
Cell
only  NC 
Sorafenib
2.5 μM shT1 shT2 
Sorafenib 2.5 μM
908
Down-Regulation of TGF-β to Sorafenib Resistance
https://doi.org/10.3349/ymj.2017.58.5.899
Fig. 5. A schematic diagram of sorafenib drug resistance by p38 activa-
tion inhibition and TGF-β down-regulation-induced sensitization of the 
resistance to sorafenib. TGF-β, transforming growth factor-β; VEGFR, 
vascular endothelial growth factor receptor; PDGFR, platelet-derived 
growth factor receptor.
Sorafenib Sorafenib
TGF-β down-regulation
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p38 activation 
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Fig. 4. Antitumor effects of the combined treatment of sorafenib and an adenovirus co-expressing shTGF-β and shHSP27 in BALB/c nude mice. (A) SNU-
449 tumors were grown in male BALB/c nude mice. Tumors were established by subcutaneous injection of 1×107 cells and were allowed to grow to an 
average size of 60−100 mm3. PBS and adenoviruses were intratumorally injected every other day for a total of 3 injections. Sorafenib (30 mg/kg) was ad-
ministered via gavage once daily from days 1 to 10. Tumor growth was measured every 2 days for more than 19 days using calipers. (B) Survival rates 
were calculated every 2 days for more than 19 days. TGF-β, transforming growth factor-β; NC, negative control; PBS, phosphate buffered saline.
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also the use of immune-competent mouse models, which would 
be more similar to clinical conditions.
In summary, a series of in vitro experiments demonstrated 
that the inhibition of p-p38 activity is the underlying mecha-
nism of sorafenib drug resistance, and that TGF-β down-regu-
lation greatly sensitizes the resistance of HCC cells to sorafenib. 
Fig. 5 provides a schematic diagram representing the results 
summarized . 
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